Cargando…

Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation

Immune exhaustion contributes to treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT) for hematological malignancies. Immune checkpoint blockade, including programmed cell death protein-1 (PD-1) blockade, is a promising strategy to improve the antitumor effect of allogen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simonetta, Federico, Pradier, Amandine, Bosshard, Carine, Masouridi-Levrat, Stavroula, Dantin, Carole, Koutsi, Aikaterini, Tirefort, Yordanka, Roosnek, Eddy, Chalandon, Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531929/ https://www.ncbi.nlm.nih.gov/pubmed/31156625 http://dx.doi.org/10.3389/fimmu.2019.01034

Ejemplares similares

Torque Teno Virus as a Potential Biomarker for Complications and Survival After Allogeneic Hematopoietic Stem Cell Transplantation
por: Pradier, Amandine, et al.
Publicado: (2020)

Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies
por: Paiano, Sandra, et al.
Publicado: (2015)

Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation
por: Masouridi-Levrat, Stavroula, et al.
Publicado: (2016)

Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies
por: Levrat, Emmanuel, et al.
Publicado: (2015)

Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Mamez, Anne-Claire, et al.
Publicado: (2021)

Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption
por: Morin, Sarah, et al.
Publicado: (2023)

CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation
por: Calderin Sollet, Zuleika, et al.
Publicado: (2023)

Rhinovirus Infections among Hematopoietic Stem Cell Transplant Recipients: A Pre-Transplant Dilemma?
por: Barral, Sébastien, et al.
Publicado: (2022)

Human pegivirus-1 replication influences NK cell reconstitution after allogeneic haematopoietic stem cell transplantation
por: Pradier, Amandine, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation in non‐Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better
por: Rebmann, Ekaterina, et al.
Publicado: (2022)

Modulation of T-bet and Eomes during Maturation of Peripheral Blood NK Cells Does Not Depend on Licensing/Educating KIR
por: Pradier, Amandine, et al.
Publicado: (2016)

T Cell Receptor Repertoire Profiling Reveals Breadth of Cellular Responses Against Sars-Cov-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Mamez, Anne-Claire, et al.
Publicado: (2022)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

T-bet and Eomesodermin in NK Cell Development, Maturation, and Function
por: Simonetta, Federico, et al.
Publicado: (2016)

Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients
por: Olearo, Flaminia, et al.
Publicado: (2020)

Longitudinal Detection of Twenty DNA and RNA Viruses in Allogeneic Hematopoietic Stem Cell Transplant Recipients Plasma
por: Zanella, Marie-Céline, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020
por: Simeunovic, Helena, et al.
Publicado: (2022)

Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT
por: Mohty, B, et al.
Publicado: (2011)

T cell receptor sequencing reveals reduced clonal breadth of T-cell responses against SARS-CoV-2 after natural infection and vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Pradier, A., et al.
Publicado: (2022)

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
por: Royston, Léna, et al.
Publicado: (2021)

P1357: IMPAIRED CELLULAR RESPONSES AGAINST SARS-COV-2 AFTER COVID-19 INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
por: Mamez, A.-C., et al.
Publicado: (2022)

Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?
por: Roth, Romain Samuel, et al.
Publicado: (2021)

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
por: Royston, Léna, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Royston, Léna, et al.
Publicado: (2022)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation
por: Glampedakis, Emmanouil, et al.
Publicado: (2021)

When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients?
por: Roth, Romain Samuel, et al.
Publicado: (2022)

Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections
por: Roth, Romain Samuel, et al.
Publicado: (2021)

Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience
por: Kronig, Ilona, et al.
Publicado: (2021)

Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8(+ )T cells by dendritic cells loaded with killed allogeneic breast cancer cells
por: Saito, Hiroaki, et al.
Publicado: (2006)

Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT
por: Masouridi-Levrat, Stavroula, et al.
Publicado: (2021)

A study of elite sport-inspired coaching for patients after allogeneic hematopoietic stem cell transplantation
por: Cuvelier, Sarah, et al.
Publicado: (2021)

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan
por: Seydoux, Claire, et al.
Publicado: (2023)

Bronchiolitis obliterans syndrome following SARS-CoV-2 infection in an allogeneic hematopoietic stem cell recipient
por: Bondeelle, Louise, et al.
Publicado: (2023)

Very severe immune thrombocytopenia following SARS-CoV-2 vaccination requiring splenectomy: a case report
por: Weiner, Marc, et al.
Publicado: (2022)

Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation
por: Simonetta, Federico, et al.
Publicado: (2017)

T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
por: Noetzli, Jasmine, et al.
Publicado: (2017)

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis
por: Berning, Philipp, et al.
Publicado: (2023)

Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation
por: Du, Wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hfst4peh57svn48obo9vq32ls3